CN117624132A - 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 - Google Patents
一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 Download PDFInfo
- Publication number
- CN117624132A CN117624132A CN202311606173.3A CN202311606173A CN117624132A CN 117624132 A CN117624132 A CN 117624132A CN 202311606173 A CN202311606173 A CN 202311606173A CN 117624132 A CN117624132 A CN 117624132A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- boric acid
- vimseltinib
- dcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TVGAHWWPABTBCX-UHFFFAOYSA-N vimseltinib Chemical compound O=C1N(C)C(NC(C)C)=NC=C1C(N=C1C)=CC=C1OC1=CC=NC(C2=CN(C)N=C2)=C1 TVGAHWWPABTBCX-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229940074572 vimseltinib Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940126192 CSF1R kinase inhibitor Drugs 0.000 title claims abstract description 8
- -1 borate compound Chemical class 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000004327 boric acid Substances 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 claims abstract description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 229940125782 compound 2 Drugs 0.000 claims abstract 3
- 229940126214 compound 3 Drugs 0.000 claims abstract 3
- 239000000543 intermediate Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 238000010009 beating Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011736 potassium bicarbonate Substances 0.000 claims 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 2
- 235000011181 potassium carbonates Nutrition 0.000 claims 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 238000001953 recrystallisation Methods 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 claims 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- 239000007806 chemical reaction intermediate Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 claims 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 238000002953 preparative HPLC Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 238000004809 thin layer chromatography Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000010189 synthetic method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 5
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 5
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KEFRAFHUHLKQCE-UHFFFAOYSA-N (1-methylpyrazol-4-yl)oxyboronic acid Chemical compound CN1C=C(OB(O)O)C=N1 KEFRAFHUHLKQCE-UHFFFAOYSA-N 0.000 description 1
- TYPVHTOETJVYIV-UHFFFAOYSA-N 2,4-dichloropyridine Chemical compound ClC1=CC=NC(Cl)=C1 TYPVHTOETJVYIV-UHFFFAOYSA-N 0.000 description 1
- IXJSDKIJPVSPKF-UHFFFAOYSA-N 4-bromo-1-methylpyrazole Chemical group CN1C=C(Br)C=N1 IXJSDKIJPVSPKF-UHFFFAOYSA-N 0.000 description 1
- AFPIOOKDVFPXTI-UHFFFAOYSA-N 5-bromo-2-chloro-3-methylpyrimidin-4-one Chemical compound CN1C(Cl)=NC=C(Br)C1=O AFPIOOKDVFPXTI-UHFFFAOYSA-N 0.000 description 1
- WMUKVIWQEQZDPP-UHFFFAOYSA-N 6-chloro-2-methylpyridin-3-ol Chemical compound CC1=NC(Cl)=CC=C1O WMUKVIWQEQZDPP-UHFFFAOYSA-N 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
本发明属药物化学合成技术领域,具体为一种CSF‑1R激酶抑制剂Vimseltinib(DCC‑3014)的制备方法。本发明合成方法反应步骤为:由原料6‑卤代‑2‑甲基吡啶‑3‑醇(1)与硼酸或者硼酸酯类化合物(5)经过suzuki偶联反应得到关键中间体化合物2,再与2,4‑二卤代吡啶(6)在碱性条件下反应得到化合物3,最后再与硼酸或者硼酸酯类化合物(7a‑7b)反应得到目标化合物Vimseltinib(DCC‑3014)(4)
Description
技术领域
本发明属于化学药物合成领域,涉及一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法
背景技术
腱鞘巨细胞瘤(TGCT)是一种罕见的局部侵袭性肿瘤,集落刺激因子1(CSF1)的过度表达会驱动巨噬细胞的聚集,从而导致局部炎症和关节破坏。患者通常会出现衰弱的症状,造成严重的疾病负担,在大多数情况下,肿瘤内少量肿瘤细胞CSF1基因改变,导致CSF1过度产生。对于那些不适合手术治疗的肿瘤患者来说,治疗方案的需求仍未得到满足。目前,靶向CSF1R的小分子抑制剂或抗体(或其配体之一CSF1)已直接进入临床抗肿瘤治疗或潜在的免疫疗法。CSF1R抑制剂联合免疫疗法治疗癌症的结果喜忧参半,临床前研究结果令人鼓舞但尚未成功转化为临床。相比之下,临床CSF1R抑制剂作为TGCT单药治疗的结果相当有利,总体响应值较好,取得不错的成效。
目前有一个获批的CSF1R抑制剂,Pexidartinib,对TGCT患者效果不错,但有肝毒性,限制其应用。针对CSF1R靶点,还是有临床需求。针对此,Deciphera公司开发了Vimseltinib(DCC-3014),目前已进入临床。与上市药Pexidartinib相比,Vimseltinib具有更大的优势,表现出更好的选择性,包括对一些同源性较近的蛋白,具有很好的应用前景。
发明内容
鉴于上述情况,CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备非常重要。本发明人通过实验研究解决了该化合物的技术问题,其反应路线如下:
本合成方案的具体步骤为:
1)由原料6-卤代-2-甲基吡啶-3-醇(1)与(2-(异丙基氨基)-1-甲基-6-氧代-1,6-二氢嘧啶-5-基)硼酸(5a)或者2-(异丙基氨基)-3-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)嘧啶-4(3H)-酮(5b)经过suzuki偶联反应得到化合物5-(5-羟基-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(2);
其中,X1=Cl、Br、I
2)步骤1)所得到的5-(5-羟基-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(2)与2,4-二卤代吡啶(6)在碱性条件下反应得到化合物5-(5-((2-卤代吡啶-4-基)氧基)-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(3);
其中X2=Cl、Br、I
3)最后与1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-1H-吡唑(7b)或者(1-甲基-1H-吡唑-4-基)硼酸(7a)反应得到目标化合物Vimseltinib(DCC-3014)(4)。
具体实验方式
下面通过实施例对本发明作进一步描述说明,但并不因此而限制本发明的内容。
中间体的制备
中间体2-(异丙基氨基)-3-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)嘧啶-4(3H)-酮和(2-(异丙基氨基)-1-甲基-6-氧代-1,6-二氢嘧啶-5-基)硼酸的制备
将化合物5-溴-2-氯-3-甲基嘧啶-4(3H)-酮(1g,4mmol)、异丙胺(0.8g,14mmol)和DIEA(1.8g,14mmol)溶于THF(5mL)中,于氮气条件下室温反应过夜。通过LC-MS监测反应,浓缩得到化合物5-溴-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(1g)。
将化合物5-溴-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(1g,2mol)、联硼酸频那醇酯(0.2g,8mol)、2-二环己基磷-2,4,6-三异丙基联苯(0.15g,0.4mmol)、醋酸钾(1.15g,12mmol)和三(二亚苄基丙酮)钯(0.2g,0.2mmol)溶于1,4-二氧六环(10mL)中。在氮气条件下,于70℃搅拌反应3h,得到化合物2-(异丙基氨基)-3-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)嘧啶-4(3H)-酮或者(2-(异丙基氨基)-1-甲基-6-氧代-1,6-二氢嘧啶-5-基)硼酸。
中间体1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-1H-吡唑或者(1-甲基-1H-吡唑-4-基)硼酸的制备
用与中间体2-(异丙基氨基)-3-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)嘧啶-4(3H)-酮第二步(其中原料换为4-溴-1-甲基-1H-吡唑)相似的制备方法得到化合物1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-1H-吡唑或者(1-甲基-1H-吡唑-4-基)硼酸。
实施例1
步骤A
将化合物6-氯-2-甲基吡啶-3-醇(72mg,0.5mmol)溶于10mL的H2O:EtOH(1:1)混合溶剂中,向混合物中加入(2-(异丙基氨基)-1-甲基-6-氧代-1,6-二氢嘧啶-5-基)硼酸(116mg,0.55mmol)和碳酸钾(76mg,0.55mmol)。然后加入PdNPs催化剂(0.4mmol%Pd),在60℃下剧烈搅拌10分钟。将反应混合物加入0.2mol/L氢氧化钠溶液(1.5mL)中,用乙酸乙酯(3mL)萃取两次。合并有机层,干燥,得到化合物5-(5-羟基-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(128.8mg,产率94%)。LC-MS(ESI):m/z=274.3[M+H]+。
步骤B
将中间体5-(5-羟基-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(86mg,0.315mmol)溶于4ml DMA中并真空脱气,并用叔丁醇钾(36.5mg,0.325mmol)处理。将所得混合物在室温下搅拌30分钟,加入2,4-二氯吡啶(40mg,0.27mmol),并将混合物在80℃下加热12小时。减压除去溶剂,得到残留物。用EtOAc(2x)萃取,然后用盐水洗涤合并有机相,用无水MgSO4干燥,过滤,真空浓缩。粗品通过硅胶色谱法纯化,得到化合物5-(5-((2-卤代吡啶-4-基)氧基)-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(95mg,产率80%)。LC-MS(ESI):m/z=385.9[M+H]+。
步骤C
将化合物5-(5-((2-卤代吡啶-4-基)氧基)-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(54mg,0.14mmol)、(1-甲基-1H-吡唑-4-基)硼酸(35mg,0.28mmol)、[1,1‘-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(11.6mg,10mol%)、碳酸钠(70mg,0.7mmol)溶于1,2-二甲氧基乙烷(10mL)和水(2.5mL)的混合物中,在氩气条件,80℃搅拌反应8小时。蒸发除去溶剂,残余物通过柱层析纯化,得到目标化合物Vimseltinib(DCC-3014)(59mg 99%)LC-MS(ESI):m/z=431.5[M+H]+,1H NMR(400MHz,CDCl3)δ1.24(d,6H),2.36(s,3H),3.38(s,3H),3.86(s,3H),4.34(dq,1H),6.61(dd,1H),7.07(d,1H),7.25(d,1H),7.53(d,1H),7.98(s,1H),8.29(d,1H),8.37(d,1H),8.69(s,1H)。
表一:6-卤代-2-甲基吡啶-3-醇(1)与硼酸或者硼酸酯类化合物(5)经过suzuki偶联反应得到关键中间体(2)
表二:化合物5-(5-((2-卤代吡啶-4-基)氧基)-6-甲基吡啶-2-基)-2-(异丙基氨基)-3-甲基嘧啶-4(3H)-酮(3)与硼酸或者硼酸酯类化合物(7)经过suzuki偶联反应得到目标化合物Vimseltinib(DCC-3014)(4)
上述实例仅用于说明本发明的实施方式,但本发明不仅仅局限于上述实例。在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内,本发明要求保护范围由权利要求书及其等效物界定。
Claims (4)
1.一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法,其特征在于,具体步骤为:
1)由原料6-卤代-2-甲基吡啶-3-醇与硼酸或者硼酸酯类化合物(5a-5b)经过suzuki偶联反应得到关键中间体2;
2)化合物2再与2,4-二卤代吡啶在碱性条件下反应得到化合物3;
3)最后再与硼酸或者硼酸酯类化合物(7a-7b)suzuki偶联反应得到目标化合物Vimseltinib(DCC-3014)(4)。
2.如权利要求1所述的一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法,其特征在于,步骤(1)和步骤(2)中,卤素取代基独立地选自Cl、Br、I中的一种;步骤(1)和步骤(3)中的反应中间体,可以选自硼酸类化合物或者硼酸酯类化合物中的一种。
3.如权利要求1所述的一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法,其特征在于,步骤(1)和步骤(3)中,suzuki偶联反应反应温度选自10-200℃,反应时间选自0-72h,溶剂选自乙醚、乙腈、乙醇、THF、DMF、DME、1,4-二氧六环、H2O、NMP、DMA、DMSO、苯、甲苯、1,2-二甲氧基乙烷中的一种或者几种。反应所用的催化剂可选自为双(三苯基膦)-二氯化钯、二(三苯基膦)二茂铁二氯化钯、二(三苯基膦)二茂铁二氯化钯二氯甲烷复合物、Pd2(dba)3、pd(dppe)Cl2、四三苯基磷钯、二(三苯基膦)二茂铁二氯化镍中的一种或几种,化合物的0.01%-20%(M/M摩尔比),反应中所用的碱选自三乙胺、乙二胺、二异丙基乙胺、咪唑、哌啶、吡啶、CsCO3、KOAc、NaOAc、K2CO3、Na2CO3、Li2CO3、tBuOK、tBuONa、K3PO4、NaOH、KOH、Ba(OH)2中的一种。用量的1-10倍(M/M摩尔比)。纯化可以选自过柱、打浆或者重结晶。
4.如权利要求1所述的一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法,其特征在于,步骤(2)中,碱选自叔丁醇钾、叔丁醇钠、叔戊醇钾、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸铯、碳酸氢铯、磷酸钾和磷酸氢二钾中的一种或几种。在一些优选的实施方案中,所述碱选自碳酸氢钾和碳酸钾。溶剂选自1-甲基-2-吡咯烷酮(NMP)、N,N-二甲基甲酰胺(DMF)和N,N-二甲基苯胺(DMA)中的一种或几种,反应温度选自60-130℃,纯化可以选自过柱子、打浆、Prep-TLC、Prep-HPLC或者重结晶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311606173.3A CN117624132A (zh) | 2023-11-28 | 2023-11-28 | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311606173.3A CN117624132A (zh) | 2023-11-28 | 2023-11-28 | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117624132A true CN117624132A (zh) | 2024-03-01 |
Family
ID=90028209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311606173.3A Pending CN117624132A (zh) | 2023-11-28 | 2023-11-28 | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117624132A (zh) |
-
2023
- 2023-11-28 CN CN202311606173.3A patent/CN117624132A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI787018B (zh) | 轉染過程重排之抑制劑 | |
JPS6122046A (ja) | スチルベン誘導体 | |
WO2016041508A1 (zh) | 一种噁唑烷酮类化合物及其中间体的制备方法 | |
CN108047261A (zh) | 一种克立硼罗的制备方法 | |
MX2011003820A (es) | Metodos para preparar oxazolidinonas y composiciones que las contienen. | |
CN105777710B (zh) | 一种艾乐替尼的合成方法 | |
CN107936029B (zh) | 一种合成瑞博西尼的方法 | |
CN105541844B (zh) | 一种高纯度利拉利汀的简易制备方法 | |
CN111848607A (zh) | 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途 | |
KR20200131241A (ko) | 2종의 4-{[(2s)-2-{4-[5-클로로-2-(1h-1,2,3-트리아졸-1-일)페닐]-5-메톡시-2-옥소피리딘-1(2h)-일}부타노일]아미노}-2-플루오로벤즈아미드 유도체의 제조 방법 | |
JPH06234690A (ja) | ビフェニル誘導体の製法 | |
CN111635373B (zh) | 多环磺酰胺类RORγ调节剂 | |
CN117624132A (zh) | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 | |
CN116496223A (zh) | 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法 | |
CN111747975B (zh) | 贝达喹啉消旋体及其中间体的制备方法 | |
WO2014022975A1 (zh) | N-(4-(3-氨基-1h-吲唑-4-基)苯基)-n'-(2-氟-5-甲基苯基)脲及其中间体的制备方法 | |
CN111718295B (zh) | 一种高纯度米力农的制备方法 | |
CN111718292B (zh) | 一种米力农中间体化合物 | |
JPWO2018168899A1 (ja) | ベンズイミダゾール誘導体の製造方法 | |
WO2019144781A1 (zh) | 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用 | |
CN109384708B (zh) | 一种Akt抑制剂中间体SM1及其制备方法 | |
CN111087358B (zh) | 普赛莫德的制备方法 | |
JP5711669B2 (ja) | スピロケタール誘導体の製造方法 | |
JP5250693B2 (ja) | カルボン酸化合物の製造方法 | |
CN117924249A (zh) | 一种jak1抑制剂azd4604的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |